Immunotherapy of Colorectal and Anal Carcinoma

Tomášek, Jiří; Kiss, Igor

doi:10.14735/amko20173s62

Cited by 4 publications

(3 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A partir da seleção e análise dos 17 artigos, fica evidente que a imunoterapia é uma alternativa promissora, quando comparada aos tratamentos clássicos [8][9][10][11] , uma vez que possui alta eficácia, é menos invasiva e proporciona melhor prognóstico pautado na resposta clínica, na taxa de sobrevivência e na progressão da doença, sendo que em casos iniciais, esses benefícios podem ser ainda maiores.…”

Section: Resultsunclassified

Aplicação Da Imunoterapia No Sus: Impactos Éticos E Financeiros

ALENCAR

BISSOLI

HANSEN

et al. 2022

RMP

View full text Add to dashboard Cite

RESUMO - Dados do Instituto Nacional do Câncer estimam que o Brasil terá 625 mil novos casos de câncer a cada ano do triênio 2020-2022. O Brasil, único país da América Latina com um sistema universal de saúde, apresentou grande avanço no tratamento do câncer. Nesse ínterim inclui-se a imunoterapia. Entretanto, o desafio ainda é longo e de custo muito elevado assim, o objetivo desta revisão foi discutir acerca da disponibilidade geral de imunoterapia no SUS. Assim, foi realizda pesquisa bibliográfica no Pubmed e Scielo com os descritores “Imunoterapia”, “Sistema Único de Saúde” e “Oncologia”. Selecionou-se 17 artigos. Em conclusão, a partir da incorporação da imunoterapia no SUS, estima-se aumento considerável na sobrevida. Todavia, a carência da disponibilidade orçamentária atrasa a implementação do tratamento. Ademais, são necessárias mais pesquisas e novas formas de seleção dos pacientes para a disponibilidade do tratamento a fim de não prejudicar o sistema público.

show abstract

Section: Resultsunclassified

Aplicação Da Imunoterapia No Sus: Impactos Éticos E Financeiros

ALENCAR

BISSOLI

HANSEN

et al. 2022

RMP

View full text Add to dashboard Cite

show abstract

“…Treatment options for CRC are complex, but it must be emphasized that only some patients can undergo radical treatment of metastases in the sense of resection with curative intent. The treatment is usually based on combined chemotherapy targeting primarily the vascular endothelial growth factor receptor (VEGFR) or the epidermal growth factor (epidermal growth factor receptor–EGFR) signaling pathways ( 2 ). Unfortunately, not all patients can be treated by these selective drugs, especially EGFR inhibitors.…”

Section: Introductionmentioning

confidence: 99%

The Role of Tumor Microenvironment and Immune Response in Colorectal Cancer Development and Prognosis

Wozniaková

Škarda

Raška³

2022

Pathol. Oncol. Res.

View full text Add to dashboard Cite

Colorectal cancer (CRC) is one of the most common cancers worldwide. The patient’s prognosis largely depends on the tumor stage at diagnosis. The pathological TNM Classification of Malignant Tumors (pTNM) staging of surgically resected cancers represents the main prognostic factor and guidance for decision-making in CRC patients. However, this approach alone is insufficient as a prognostic predictor because clinical outcomes in patients at the same histological tumor stage can still differ. Recently, significant progress in the treatment of CRC has been made due to improvements in both chemotherapy and surgical management. Immunotherapy-based approaches are one of the most rapidly developing areas of tumor therapy. This review summarizes the current knowledge about the tumor microenvironment (TME), immune response and its interactions with CRC development, immunotherapy and prognosis.

show abstract

“…Furthermore, tumor immunotherapy, especially immune checkpoint inhibitors (ICIs), has shown exciting clinical success in various solid tumor treatments 4 . Unfortunately, the prognosis for individuals diagnosed with CRC at an advanced stage remains poor, and only a few CRC individuals with microsatellite instability high, approximately 4-5% of mCRC population, could be benefiting from ICIs 5 . Thus, more reliable and accurate biomarkers and potential therapeutic targets should be explored to improve the diagnosis, prognosis, and therapeutic effect of CRC individuals.…”

Section: Introductionmentioning

confidence: 99%

Cuproptosis is correlated with clinical status, tumor immune microenvironment and immunotherapy in colorectal cancer: a multi-omic analysis

Shao

Fan

Yang

et al. 2022

Preprint

View full text Add to dashboard Cite

Copper, like double edged sword, either too little or too much can lead to cell death. Cuproptosis, a novel identified cell death form induced by copper, is characterized by aggregation of lipoylated mitochondrial enzymes and the destabilization of FeS cluster proteins. However, the function and potential clinical value of cuproptosis in colorectal cancer remains largely unknown. In this study, 16 cuproptosis related molecules (CPRMs) were identified and analyzed by transcriptomics, genomics, and single cell transcriptome profiling from multiple databases. We established two cuproptosis related molecular phenotypes (CMP1 and 2) to distinguish CRC individuals, in which there were significantly differences in prognosis, biological function, somatic mutation frequency, immune cell infiltration in CRC individuals. A novel cuproptosis related scoring system (CuproScore) was also constructed to predict the prognosis of CRC individuals, TME and the response to immunotherapy. Of notion, the value of CuproScore was also confirmed in our transcriptome cohort, demonstrating that CRC individuals in the high CuproScore group tended to have higher immune cell infiltrations and higher immune checkpoint expression. We also checked and analyzed the expression and clinical significance of 16 CPRMs in CRC cell lines and CRC tissues. This study indicated that cuproptosis and CPRMs played significant role in CRC progression and in modeling the TME. Inducing cuproptosis may be a useful tool for tumor therapy in the future.

show abstract

Immunotherapy of Colorectal and Anal Carcinoma

Cited by 4 publications

References 9 publications

Aplicação Da Imunoterapia No Sus: Impactos Éticos E Financeiros

Aplicação Da Imunoterapia No Sus: Impactos Éticos E Financeiros

The Role of Tumor Microenvironment and Immune Response in Colorectal Cancer Development and Prognosis

Cuproptosis is correlated with clinical status, tumor immune microenvironment and immunotherapy in colorectal cancer: a multi-omic analysis

Contact Info

Product

Resources

About